TGR1202 in Relapsed and Refractory Follicular Lymphoma

Summary

The primary objective is to determine the overall response rate (ORR) of TGR-1202 in R/R FL. Secondary Objectives * Determine the genetic and other novel biological markers that may be predictive of response or resistance to TGR-1202 in patients with relapsed or refractory FL. * Describe the Progression Free Survival (PFS), Duration of Response (DoR) after treatment with TGR-1202. * Describe the number of dose delays and dose reductions and other safety profile.

Timeline

Start

2017-08-20

Primary completion

2020-06-30

Completion

2020-06-30

Drugs

Indications